Evidence map›Paper›PMID 29870540›Full record

ArticlePloS one2018

Cigarette toxin 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces experimental pancreatitis through α7 nicotinic acetylcholine receptors (nAChRs) in mice.

A A Alahmari, B Sreekumar, V Patel, M Ashat, M Alexandre, A K Uduman, E O Akinbiyi, A Ceplenski, C A Shugrue, T R Kolodecik and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Blockade of the protease ADAM17 ameliorates experimental pancreatitis.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

A A AlahmariDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
B SreekumarDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
V PatelDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
M AshatDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
M AlexandreDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
A K UdumanDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
E O AkinbiyiDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
A CeplenskiDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
C A ShugrueDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
T R KolodecikDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
N TashkandiDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.ORCID 0000-0002-7891-9936
S W MessengerDepartment of Nutritional Sciences, University of Wisconsin, Madison, Wisconsin, United States of America.
G E GroblewskiDepartment of Nutritional Sciences, University of Wisconsin, Madison, Wisconsin, United States of America.
F S GorelickDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.
E C ThrowerDepartment of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America.ORCID 0000-0003-2095-2343
Yale University · USUniversity of Wisconsin–Madison · US

Funding

Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
TRAINING IN NUTRITIONT32DK007665 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI GUY E GROBLEWSKI, Chi- Liang Eric Yen · 1993 to 2026
$9.2M
The role of cigarette smoke toxin and alcohol in pancreatitisR21AA020847 · NIAAA · YALE UNIVERSITY · PI THROWER, EDWIN C · 2012 to 2013
$333k
NIAAA NIH HHS R21 AA020847NIDDK NIH HHS P30 DK034989
6 · The paper itself

Abstract

Clinical studies have shown that cigarette smoking is a dose-dependent and independent risk factor for acute pancreatitis. Cigarette smoke contains nicotine which can be converted to the potent receptor ligand and toxin, NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone]. Previously, we have shown that NNK induces premature activation of pancreatic zymogens in rats, an initiating event in pancreatitis, and this activation is prevented by pharmacologic inhibition of nicotinic acetylcholine receptors (nAChR). In this study, we determined whether NNK mediates pancreatitis through the α7 isoform of nAChR using α7nAChR knockout mice. PCR analysis confirmed expression of non-neuronal α7nAChR in C57BL/6 (WT) mouse and human acinar cells. NNK treatment stimulated trypsinogen activation in acini from WT but not α7nAChR-/- mice. NNK also stimulated trypsinogen activation in human acini. To further confirm these findings, WT and α7nAChR-/- mice were treated with NNK in vivo and markers of pancreatitis were measured. As observed in acini NNK treatment induced trypsinogen activation in WT but not α7nAChR-/- mice. NNK also induced other markers of pancreatitis including pancreatic edema, vacuolization and pyknotic nuclei in WT but not α7nAChR-/- animals. NNK treatment led to increased neutrophil infiltration, a marker of inflammation, in WT mice and to a significantly lesser extent in α7nAChR-/- mice. We also examined downstream targets of α7nAChR activation and found that calcium and PKC activation are involved down stream of NNK stimulation of α7nAChR. In this study we used genetic deletion of the α7nAChR to confirm our previous inhibitor studies that demonstrated NNK stimulates pancreatitis by activating this receptor. Lastly, we demonstrate that NNK can also stimulate zymogen activation in human acinar cells and thus may play a role in human disease.

Indexed as

alpha7 Nicotinic Acetylcholine ReceptorAnimalsCarcinogensCell ProliferationGene DeletionHumansMiceMice, KnockoutNicotianaNicotineNitrosaminesPancreatitis4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanonealpha7 Nicotinic Acetylcholine ReceptorCarcinogensNicotineNitrosamines

Identifiers

PMID29870540
PMCPMC5988302
OpenAlexW2806153178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.